Cancer Diagnostics: Technology
and Business Trends examines the current status of
in vivo imaging applications and in vitro cancer diagnostic tests,
as well as their future potential as important screening tools.
Cancer diagnostic technologies and assays are essential for
the detection, diagnosis, and management of cancer. For certain
cancers, methods are available for screening apparently healthy
(asymptomatic) average-risk individuals. In addition, some cancers,
such as cervical and colorectal cancers, can be detected in an
even earlier, precancerous stage of development. For example,
remote sample tests being developed by Epigenomics in partnership
with Roche promise to identify more people with Stage I colorectal
cancer and could dramatically decrease the mortality associated
with this disease. These tests may enter the market as early
The diverse applications in cancer screening, monitoring, and
diagnostics require a broad range of tools. Cancer
Diagnostics: Technology and Business Trends profiles
selected companies competing in this market to develop such technologies
and apply them in novel and innovative ways. Topics evaluated
in this report include the following:
- New molecular imaging technologies, such as positron emission
- Advances in in vitro diagnostic colorectal cancer
- Efforts to identify novel cancer biomarkers and develop
new pharmacodiagnostic cancer tests.
- The field of pharmacodiagnostics—the development
of tests to predict response to therapy or to identify the
optimal therapy for a patient. Two examples of pharmacodiagnostic
tests that are already being used—the DakoCytomation
EGFR PharmDx test, and Immunophenotyping of leukemia and lymphoma—are
- Potential opportunities for DNA methylation tests.
- Market opportunities for current tests and emerging applications.
Oncogenomics: The Future of Cancer Care
Hematological Cancer Therapeutics
About the Author
Lucy J. Sannes, Ph.D., is president
of Sannes & Associates, Inc., a consulting firm specializing
in evaluation and management of the biosciences. Before forming
Sannes & Associates, she held management positions at Genetic
Systems and Abbott Laboratories in product development, product
support, and technical marketing. Dr. Sannes received her Ph.D.
in biological chemistry from the University of Michigan and
her M.B.A. from Seattle Pacific University.